OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity in children; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Pediatric Nailing Platform | Femur, Devise Rail, Orthex, The Fassier-Duval Telescopic Intramedullary System, SLIM Nail, The GAP Nail, The Free Gliding SCFE Screw System, GIRO Growth Modulation System, PNP Tibia System, ApiFix Mid-C System, Mitchell Ponseti, VerteGlideTM, and Boston Brace 3D. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.…
OrthoPediatrics Announces Full Commercial Launch of VerteGlide® Spinal Growth Guidance System
OrthoPediatrics (NASDAQ: KIDS) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 602 employees.
The shares were at 31.74 USD on 20 November 2026, up 86.6% over 52 weeks. Its 52-week range is 14.42 USD to 34.53 USD: the price is 8.1% below the high and 120.1% above the low.
Its market capitalisation is 828.75M USD.
OrthoPediatrics reports return on equity of -11.4%, an operating margin of -8.1% and revenue up 18.6% year over year.
Its debt exceeds its cash by 66.62M USD, a debt-to-equity ratio of 0.29. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 8 analysts cover the stock, with an average rating of Buy; their mean price target of 33.88 USD is 6.7% above the current price. The next earnings report is expected on 25 February 2027.